The utility of screening in the design of trials for symptom management in cancer.
Clinical trials that test interventions for symptom management must target patients whose symptoms are severe and can benefit from participation. Screening symptoms for their severity prior to trial entry may be an important element of trial design. This research describes the utility of screening for severity of symptoms prior to entry into clinical trials for symptom management in cancer. To accomplish this, 601 cancer patients undergoing chemotherapy were assessed at screening and at the initial intervention contact, using the 0-10 rating scale for severity of nine symptoms. Post-test probabilities and likelihood ratios (LRs) were estimated across cut-offs in screening severity scores. Areas under receiver operating characteristic curves for reaching threshold of four at the initial intervention contact were estimated by a nonparametric method. It was found that screening severity scores were good predictors for identifying patients who would not reach threshold but did not always accurately predict patients who would. The cut-offs between 2 and 4 on a 0-10 scale could be used to identify patients that might benefit from receipt of interventions. For all symptoms, the LRs were greater than one across possible screening cut-offs. The findings indicate that decision rules based on screening prior to entry into cancer symptom management trials can provide reasonable discriminative accuracy by differentiating among patients who are likely to reach higher levels of severity later in the trial from those who are not. Optimal severity cut-offs can be established based on LRs and desired sensitivity and specificity.
Jeon
Sangchoon
S
School of Nursing, Yale University, New Haven, Connecticut, USA.
Given
Charles W
CW
Sikorskii
Alla
A
Given
Barbara
B
D000368:Aged; D020000:Decision Support Systems, Clinical; D005260:Female; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods*; D008875:Middle Aged; D009369:Neoplasms / Q000175:diagnosis* / Q000451:nursing*; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014481:United States / Q000453:epidemiology
J Clin Oncol. 2006 Sep 20;24(27):4485-91
16983118
Am J Epidemiol. 2006 Apr 1;163(7):670-5
16410346
J Pain Symptom Manage. 2000 Aug;20(2):104-12
10989248
Cancer Pract. 1994 Jan-Feb;2(1):57-62
8055007
Oncol Nurs Forum. 2001 Apr;28(3):465-70
11338755
J Natl Compr Canc Netw. 2003 Jul;1(3):308-31
19761067
Clin J Oncol Nurs. 2007 Oct;11(5):659-66
17962174
Cancer. 1999 Oct 15;86(8):1609-20
10526293
Support Care Cancer. 2006 Aug;14(8):825-30
16491377
J Pain Symptom Manage. 2003 Apr;25(4):307-18
12691682
Ann Intern Med. 2001 May 1;134(9 Pt  2):844-53
11346320
Cancer. 2003 Jun 1;97(11):2880-6
12767103
Support Care Cancer. 2006 Aug;14(8):792-4
16565822
Cancer. 1999 Mar 1;85(5):1186-96
10091805
Semin Hematol. 1997 Jul;34(3 Suppl 2):4-12
9253778
Cancer. 2000 Oct 1;89(7):1634-46
11013380
Ann Intern Med. 2001 May 1;134(9 Pt 1):783-5
11329237
J Natl Cancer Inst. 2005 Mar 16;97(6):448-56
15770009
Eur J Cancer. 2005 Jan;41(2):199-205
15661543
Pain. 2004 May;109(1-2):132-42
15082135
Radiology. 1982 Apr;143(1):29-36
7063747
Oncologist. 2000;5(5):353-60
11040270
Cancer Invest. 2005;23(3):229-39
15945509
J Palliat Care. 2002 Fall;18(3):150-9
12418365
J Pain Symptom Manage. 2001 Jun;21(6):456-66
11397603
Prev Vet Med. 2000 May 30;45(1-2):23-41
10802332
J Clin Epidemiol. 1999 Sep;52(9):885-92
10529029
J Natl Cancer Inst Monogr. 2004;(32):17-21
15263036